A Multi-Center, Open-label, 24-week Clinical Investigation to Evaluate Safety and Tolerability of Treatment with the Oxulumis, Suprachoroidal Drug Administration Device, Delivering 2.4mg Triamcinolone Acetonide (Triesence) in Participants with Diabetic Macular Edema (OXUCT-101)
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Triamcinolone (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Acronyms OXUCT-101
- Sponsors Oxular
Most Recent Events
- 04 Feb 2024 Status changed from recruiting to discontinued.
- 15 Oct 2023 This trial has been discontinued in Spain.
- 22 Apr 2022 New trial record